Early-Phase Adverse Effects and Management of Liposomal Amikacin Inhalation for Refractory Mycobacterium avium Complex Lung Disease in Real-World Settings

References

• Prevots DR, Shaw PA, Strickland D, et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med. 2010;182(7):970–976. doi:10.1164/rccm.201002-0310OC
   Web of Science ®Google Scholar
• Adjemian J, Olivier KN, Seitz AE, Holland SM, Prevots DR. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med. 2012;185(8):881–886. doi:10.1164/rccm.201111-2016OC
   PubMed Web of Science ®Google Scholar
• Ahn K, Kim YK, Hwang GY, Cho H, Uh Y. Continued upward trend in non-tuberculous mycobacteria isolation over 13 years in a tertiary care hospital in Korea. Yonsei Med J. 2021;62(10):903–910. doi:10.3349/ymj.2021.62.10.903
   Web of Science ®Google Scholar
• Prevots DR, Marras TK. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review. Clin Chest Med. 2015;36(1):13–34. doi:10.1016/j.ccm.2014.10.002
   PubMed Web of Science ®Google Scholar
• Schildkraut JA, Gallagher J, Morimoto K, et al. Epidemiology of nontuberculous mycobacterial pulmonary disease in Europe and Japan by Delphi estimation. Respir Med. 2020;173:106164. doi:10.1016/j.rmed.2020.106164
   PubMed Web of Science ®Google Scholar
• Namkoong H, Kurashima A, Morimoto K, et al. Epidemiology of pulmonary nontuberculous mycobacterial disease, Japan. Emerg Infect Dis. 2016;22(6):1116–1117. doi:10.3201/eid2206.151086
   PubMed Web of Science ®Google Scholar
• Morimoto K, Iwai K, Uchimura K, et al. A steady increase in nontuberculous mycobacteriosis mortality and estimated prevalence in Japan. Ann Am Thorac Soc. 2014;11(1):1–8. doi:10.1513/AnnalsATS.201303-067OC
   PubMedGoogle Scholar
• Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Clin Infect Dis. 2020;71(4):905–913. doi:10.1093/cid/ciaa1125
   PubMed Web of Science ®Google Scholar
• Wallace RJ Jr., Brown BA, Griffith DE, Girard WM, Murphy DT. Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients. Am J Respir Crit Care Med. 1996;153(6 Pt 1):1766–1772. doi:10.1164/ajrccm.153.6.8665032
   PubMed Web of Science ®Google Scholar
• Miwa S, Shirai M, Toyoshima M, et al. Efficacy of clarithromycin and ethambutol for Mycobacterium avium complex pulmonary disease. A preliminary study. Ann Am Thorac Soc. 2014;11(1):23–29. doi:10.1513/AnnalsATS.201308-266OC
   PubMedGoogle Scholar
• Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367–416. doi:10.1164/rccm.200604-571ST
   PubMed Web of Science ®Google Scholar
• Ellender CM, Law DB, Thomson RM, Eather GW. Safety of IV amikacin in the treatment of pulmonary non-tuberculous mycobacterial disease. Respirology. 2016;21(2):357–362. doi:10.1111/resp.12676
   PubMed Web of Science ®Google Scholar
• Kim OH, Kwon BS, Han M, et al. Association between duration of aminoglycoside treatment and outcome of cavitary mycobacterium avium complex lung disease. Clin Infect Dis. 2019;68(11):1870–1876. doi:10.1093/cid/ciy804
   Web of Science ®Google Scholar
• Peloquin CA, Berning SE, Nitta AT, et al. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis. 2004;38(11):1538–1544. doi:10.1086/420742
   PubMed Web of Science ®Google Scholar
• van Ingen J, Egelund EF, Levin A, et al. The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. Am J Respir Crit Care Med. 2012;186(6):559–565. doi:10.1164/rccm.201204-0682OC
   PubMed Web of Science ®Google Scholar
• Jhun BW, Yang B, Moon SM, et al. Amikacin inhalation as salvage therapy for refractory nontuberculous mycobacterial lung disease. Antimicrob Agents Chemother. 2018;62(7). doi:10.1128/AAC.00011-18
   Web of Science ®Google Scholar
• Yagi K, Ishii M, Namkoong H, et al. The efficacy, safety, and feasibility of inhaled amikacin for the treatment of difficult-to-treat non-tuberculous mycobacterial lung diseases. BMC Infect Dis. 2017;17(1):558. doi:10.1186/s12879-017-2665-5
   PubMed Web of Science ®Google Scholar
• Olivier KN, Shaw PA, Glaser TS, et al. Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease. Ann Am Thorac Soc. 2014;11(1):30–35. doi:10.1513/AnnalsATS.201307-231OC
   PubMedGoogle Scholar
• Griffith DE, Eagle G, Thomson R, et al. Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT). A prospective, open-label, randomized study. Am J Respir Crit Care Med. 2018;198(12):1559–1569. doi:10.1164/rccm.201807-1318OC
   PubMed Web of Science ®Google Scholar
• Swenson C, Lapinel NC, Ali J. Clinical management of respiratory adverse events associated with amikacin liposome inhalation suspension: results from a patient survey. Open Forum Infect Dis. 2020;7(4):ofaa079. doi:10.1093/ofid/ofaa079
   PubMed Web of Science ®Google Scholar
• Asakura T, Funatsu Y, Ishii M, et al. Health-related quality of life is inversely correlated with C-reactive protein and age in Mycobacterium avium complex lung disease: a cross-sectional analysis of 235 patients. Respir Res. 2015;16:145. doi:10.1186/s12931-015-0304-5
   PubMed Web of Science ®Google Scholar
• Inagaki T, Yagi T, Ichikawa K, et al. Evaluation of a rapid detection method of clarithromycin resistance genes in Mycobacterium avium complex isolates. J Antimicrob Chemother. 2011;66(4):722–729. doi:10.1093/jac/dkq536
   Web of Science ®Google Scholar
• Brown-Elliott BA, Iakhiaeva E, Griffith DE, et al. In vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolates. J Clin Microbiol. 2013;51(10):3389–3394. doi:10.1128/JCM.01612-13
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Susceptibility Testing of Mycobacteria, Nocardia Spp., and Other Aerobic Actinomycetes. CLSI Supplement M62. Wayne, PA: Clinical and Laboratory Standards Institute; 2018.
   Google Scholar
• Morita A, Namkoong H, Hosoya M, Hasegawa N. Laryngitis after inhalation of liposomal amikacin. Clin Case Rep. 2022;10(2):e05350. doi:10.1002/ccr3.5350
   Web of Science ®Google Scholar
• Kidogawa M, Yamasaki K, Nemoto K, Yatera K. Liposomal amikacin inhalation suspension-induced pneumonitis. Intern Med. 2022. doi:10.2169/internalmedicine.8796-21
   Web of Science ®Google Scholar
• Asakura T, Kimizuka Y, Nishimura T, et al. Serum Krebs von den Lungen-6 level in the disease progression and treatment of Mycobacterium avium complex lung disease. Respirology. 2021;26(1):112–119. doi:10.1111/resp.13886
   Web of Science ®Google Scholar
• Ohnishi H, Yokoyama A, Yasuhara Y, et al. Circulating KL-6 levels in patients with drug induced pneumonitis. Thorax. 2003;58(10):872–875. doi:10.1136/thorax.58.10.872
   PubMed Web of Science ®Google Scholar
• Bilton D, Fajac I, Pressler T, et al. Long-term amikacin liposome inhalation suspension in cystic fibrosis patients with chronic P. aeruginosa infection. J Cyst Fibros. 2021;20(6):1010–1017. doi:10.1016/j.jcf.2021.05.013
   Web of Science ®Google Scholar
• Henriette Zweijpfenning SM, Chiron R, Essink S, et al. Safety and outcomes of amikacin liposome inhalation suspension for mycobacterium abscessus pulmonary disease: a NTM-NET. Chest. 2022;162:76–81. doi:10.1016/j.chest.2022.01.015
   Web of Science ®Google Scholar
• Park HY, Jeong BH, Chon HR, Jeon K, Daley CL, Koh WJ. Lung function decline according to clinical course in nontuberculous mycobacterial lung disease. Chest. 2016;150(6):1222–1232. doi:10.1016/j.chest.2016.06.005
   PubMed Web of Science ®Google Scholar
• Wenzler E, Fraidenburg DR, Scardina T, Danziger LH. Inhaled antibiotics for gram-negative respiratory infections. Clin Microbiol Rev. 2016;29(3):581–632. doi:10.1128/CMR.00101-15
   PubMed Web of Science ®Google Scholar
• Li Z, Zhang Y, Wurtz W, et al. Characterization of nebulized liposomal amikacin (Arikace) as a function of droplet size. J Aerosol Med Pulm Drug Deliv. 2008;21(3):245–254. doi:10.1089/jamp.2008.0686
   PubMed Web of Science ®Google Scholar
• Meers P, Neville M, Malinin V, et al. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J Antimicrob Chemother. 2008;61(4):859–868. doi:10.1093/jac/dkn059
   PubMed Web of Science ®Google Scholar
• Rose SJ, Neville ME, Gupta R, Bermudez LE. Delivery of aerosolized liposomal amikacin as a novel approach for the treatment of nontuberculous mycobacteria in an experimental model of pulmonary infection. PLoS One. 2014;9(9):e108703. doi:10.1371/journal.pone.0108703
   PubMed Web of Science ®Google Scholar